|
1
|
Fan L, Strasser-Weippl K, Li JJ, St Louis
J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast
cancer in China. Lancet Oncol. 15:e279–e289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gerdes J, Li L, Schlueter C, Duchrow M,
Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873.
1991.PubMed/NCBI
|
|
3
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: A meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colozza M, Azambuja E, Cardoso F, Sotiriou
C, Larsimont D and Piccart MJ: Proliferative markers as prognostic
and predictive tools in early breast cancer: Where are we now? Ann
Oncol. 16:1723–1739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ: Panel members:
Personalizing the treatment of women with early breast cancer:
highlights of the St Gallen International Expert Consensus on the
Primary Therapy of Ealy Breast Cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown JR, DiGiovanna MP, Killelea B,
Lannin DR and Rimm DL: Quantitative assessment Ki-67 score for
prediction of response to neoadjuvant chemotherapy in breast
cancer. Lab Invest. 94:98–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diehn M, Nardini C, Wang DS, McGovern S,
Jayaraman M, Liang Y, Aldape K, Cha S and Kuo MD: Identification of
noninvasive imaging surrogates for brain tumor gene-expression
modules. Proc Natl AcadSci USA. 105:5213–5218. 2008. View Article : Google Scholar
|
|
8
|
Basu S, Kwee TC, Gatenby R, Saboury B,
Torigian DA and Alavi A: Evolving role of molecular imaging with
PET in detecting and characterizing heterogeneity of cancer tissue
at the primary and metastatic sites, a plausible explanation for
failed attempts to cure malignant disorders. Eur J Nucl Med Mol
Imaging. 38:987–991. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rutman AM and Kuo MD: Radiogenomics:
Creating a link between molecular diagnostics and diagnostic
imaging. Eur J Radiol. 70:232–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yip SS and Aerts HJ: Applications and
limitations of radiomics. Phys Med Biol. 61:R150–R166. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lambin P, Rios-Velazquez E, Leijenaar R,
Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R,
Boellard R, Dekker A and Aerts HJ: Radiomics: Extracting more
information from medical images using advanced feature analysis.
Eur J Cancer. 48:441–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar V, Gu Y, Basu S, Berglund A,
Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A,
Fenstermacher D, et al: Radiomics: The process and the challenges.
Magn Reson Imaging. 30:1234–1248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Limkin EJ, Sun R, Dercle L, Zacharaki EI,
Robert C, Reuzé S, Schernberg A, Paragios N, Deutsch E and Ferté C:
Promises and challenges for the implementation of computational
medical imaging (radiomics) in oncology. Ann Oncol. 28:1191–1206.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nie K, Chen JH, Yu HJ, Chu Y, Nalcioglu O
and Su MY: Quantitative analysis of lesion morphology and texture
features for diagnostic prediction in breast MRI. Acad Radiol.
15:1513–1525. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim SG, Freed M, Leite APK, Zhang J, Seuss
C and Moy L: Separation of benign and malignant breast lesions
using dynamic contrast enhanced MRI in a biopsy cohort. J Magn
Reson Imaging. 45:1385–1393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang RF, Chen HH, Chang YC, Huang CS,
Chen JH and Lo CM: Quantification of breast tumor heterogeneity for
ER status, HER2 status, and TN molecular subtype evaluation on
DCE-MRI. Magn Reson Imaging. 34:809–819. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan M, Li H, Wang S, Zheng B, Zhang J and
Li L: Radiomic analysis reveals DCE-MRI features for prediction of
molecular subtypes of breast cancer. PLoS One. 12:e01716832017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou SS, Gombos EC, Chikarmane SA, Giess
CS and Jayender J: Computer-aided heterogeneity analysis in breast
MR imaging assessment of ductal carcinoma in situ: Correlating
histologic grade and receptor status. J Magn Reson Imaging.
46:1748–1759. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Agner SC, Rosen MA, Englander S,
Tomaszewski JE, Feldman MD, Zhang P, Mies C, Schnall MD and
Madabhushi A: Computerized image analysis for identifying
triple-negative breast cancers and differentiating them from other
molecular subtypes of breast cancer on dynamic contrast-enhanced MR
images: A feasibility study. Radiology. 272:91–99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sutton EJ, Dashevsky BZ, Oh JH,
Veeraraghavan H, Apte AP, Thakur SB, Morris EA and Deasy JO: Breast
cancer molecular subtype classifier that incorporates MRI features.
J Magn Reson Imaging. 44:122–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lankton S and Tannenbaum A: Localizing
region-based active contours. IEEE Trans Image Process.
17:2029–2039. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodenacker K and Bengtsson E: A feature
set for cytometry on digitized microscopic images. Anal Cell
Pathol. 25:1–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haralick R, Shanmugam K and Dinstein I:
Texture parameters for image classification. IEEE Trans SMC.
3:610–621. 1973.
|
|
24
|
Matsubara N, Mukai H, Masumoto M, Sasaki
M, Naito Y, Fujii S and Wada N: Survival outcome and reduction rate
of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast
cancer patients with non-pCR. Breast Cancer Res Treat. 147:95–102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li H, Han X, Liu Y, Liu G and Dong G: Ki67
as a predictor of poor prognosis in patients with triple-negative
breast cancer. Oncol Lett. 9:149–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
